Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : U.S. COVID-19 vaccine trial results likely in late-Jan, says health official

12/02/2020 | 03:14pm EST
A small shopping basket filled with vials labeled

(Reuters) - AstraZeneca Plc will likely get results of its U.S. COVID-19 vaccine trial in late-January and could potentially file for an emergency authorization, the chief adviser for the U.S. government's Operation Warp Speed program said on Wednesday.

The British drugmaker and Oxford University have already published interim efficacy results from their UK trial in November, but the results have raised questions among scientists.

The company said the vaccine could be 90% effective when given as a half dose followed by a full dose, based on a relatively small number of volunteers, while overall effectiveness was around 70%.

Speaking at a U.S. Department of Health and Human Services meeting, OWS chief adviser Moncef Slaoui said the large set of contrasting data coming out from the UK and Brazil trials may not be enough to ensure the vaccine receives the U.S. Food and Drug Administration's emergency use authorization.

"Unless there is a very clear explanation based on facts and data of what's behind those two numbers (on efficacy), it's very likely that package would not be sufficient for (FDA) approval," he said.

AstraZeneca resumed its U.S. trial in October after halting the study on Sept. 6 after a report of a serious neurological illness in a participant in the UK.

"I still expect that somewhere in January maybe, more towards the second half of January, data will become available and potentially an emergency use authorization could be filed," Slaoui said, referring to the U.S. trial.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Sriraj Kalluvila)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.66% 7777 Delayed Quote.6.19%
EURO / BRAZILIAN REAL (EUR/BRL) -0.01% 6.6525 Delayed Quote.2.58%
All news about ASTRAZENECA PLC
04:52pChina Overtakes U.S. as World's Leading Destination for Foreign Direct Invest..
DJ
03:28pASTRAZENECA : Ecuador approves use of AstraZeneca vaccine for COVID-19
RE
01:23pChina Overtakes U.S. as World's Leading Destination for Foreign Direct Invest..
DJ
01:14pChina Overtakes U.S. as World's Leading Destination for Foreign Direct Invest..
DJ
11:36aPFIZER : UK vaccination drive expands as virus toll nears 100,000
AQ
10:11aASTRAZENECA : Italy to take legal action on COVID vaccine delays to get doses
RE
09:00aASTRAZENECA : Italy to take legal action over COVID vaccine delays to secure dos..
RE
05:24aASTRAZENECA : EU says it will make vaccine companies respect supply contracts - ..
RE
03:21aASTRAZENECA : India to give homegrown vaccine in seven more states this week
RE
01/23THE LATEST : Chicago opens restaurants, some bars with limits
AQ
More news
Financials (USD)
Sales 2020 26 404 M - -
Net income 2020 2 955 M - -
Net Debt 2020 13 238 M - -
P/E ratio 2020 42,5x
Yield 2020 2,65%
Capitalization 140 B 139 B -
EV / Sales 2020 5,79x
EV / Sales 2021 4,98x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 126,47 $
Last Close Price 106,39 $
Spread / Highest target 46,7%
Spread / Average Target 18,9%
Spread / Lowest Target -15,2%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC6.19%139 483
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159